June 29, 2020 - Shares of Novavax (NVAX) have been upgraded to buy with a $101 price target at H.C Wainwright. The firm sees the Covid-19 vaccine NVX-CoV2373 potentially doing $400 million in annual sales.
Novavax (NVAX) stock was just $5 in early 2020 but has soared to new heights in the last few months. NVAX has been public for nearly 25 years but has always been a failure. Could this time be different?
Keep an eye on the Lemonade (LMND) IPO coming this week - https://daytradingstockblog.blogspot.com/2020/06/lemonade-lmnd-stock-ipo-ai-bots-replace.html
Showing posts with label stock upgrade. Show all posts
Showing posts with label stock upgrade. Show all posts
Monday, June 29, 2020
Saturday, October 19, 2013
Potbelly (PBPB) Stock Upgraded - 2014 Price Target $35
The Potbelly (PBPB) IPO two weeks ago was red hot, hitting $33.57, dropping back to $30, and then running back up to $33.90 during a horrible period in the time, the Gov't shut down crisis. Since then, PBPB stock dropped all the way down to $23.76 on some negative press.
In the last 4 trading sessions, Potbelly stock has rebounded $3 and is trading $1 shy of it's 10 day moving average. So now what? Will Potbelly (PBPB) continue the break out and close above the 10 day moving average or will the stock take a new leg lower and bottom somewhere between $21-$23?
While everyone seems to be hating on Potbelly (PBPB) in the mid $20's, I love it down here. The brand is solid, the sandwiches are amazing, and they are growing fast. Margins are juicy with most stores squeezing out 20-21% profit margins. Potbelly currently has 16 new restaurant locations in the pipeline. I think they are going to grow a lot faster than Wall St thinks. It will be interesting to see the headlines one year from now because if what I'm thinking comes true, we will be looking at a $35-$40 stock.
Potbelly (PBPB) is no Noodles & Company (NDLS) or Chipotle Mexican Grill (CMG) but don't count this underdog out. If they start beating earnings, revenue, and raising guidance, this stock will rip and rip hard!
My take: Potbelly (PBPB) is a buy below $25, a strong buy below $23. My PBPB 2014 Price Target is $35-$40 per share.
For more information on what stock to buy, join my stock picks group to follow my trades. For more information in the top stocks in 2013, visit these links - Top Stocks 2013 - Top Penny Stocks 2013 - Stocks to Buy 2014
In the last 4 trading sessions, Potbelly stock has rebounded $3 and is trading $1 shy of it's 10 day moving average. So now what? Will Potbelly (PBPB) continue the break out and close above the 10 day moving average or will the stock take a new leg lower and bottom somewhere between $21-$23?
While everyone seems to be hating on Potbelly (PBPB) in the mid $20's, I love it down here. The brand is solid, the sandwiches are amazing, and they are growing fast. Margins are juicy with most stores squeezing out 20-21% profit margins. Potbelly currently has 16 new restaurant locations in the pipeline. I think they are going to grow a lot faster than Wall St thinks. It will be interesting to see the headlines one year from now because if what I'm thinking comes true, we will be looking at a $35-$40 stock.
Potbelly (PBPB) is no Noodles & Company (NDLS) or Chipotle Mexican Grill (CMG) but don't count this underdog out. If they start beating earnings, revenue, and raising guidance, this stock will rip and rip hard!
My take: Potbelly (PBPB) is a buy below $25, a strong buy below $23. My PBPB 2014 Price Target is $35-$40 per share.
For more information on what stock to buy, join my stock picks group to follow my trades. For more information in the top stocks in 2013, visit these links - Top Stocks 2013 - Top Penny Stocks 2013 - Stocks to Buy 2014
Monday, November 7, 2011
Inhibitex, Inc. (INHX) Stock Upgraded - 2012 Price Target $12
By Tim - http://blackberrystocks.com
November 7, 2011 - Inhibitex, Inc. (INHX) stock was upgraded this morning which is causing the stock to pop for the second day. Brean Murray is out with an investor note calling Inhibitex, Inc. (INHX) a buy with a 2012 price target of $12 per share. If the trial becomes successful, Inhibitex, Inc. (INHX) could compare to the likes of Pharmasset, Inc. (VRUS) which has a similar Hep-C drug.
November 7, 2011 - Inhibitex, Inc. (INHX) stock was upgraded this morning which is causing the stock to pop for the second day. Brean Murray is out with an investor note calling Inhibitex, Inc. (INHX) a buy with a 2012 price target of $12 per share. If the trial becomes successful, Inhibitex, Inc. (INHX) could compare to the likes of Pharmasset, Inc. (VRUS) which has a similar Hep-C drug.
Inhibitex, Inc. (INHX) rallied up into the $9's on Friday after releasing the following news. INHX stock is currently trading at $9.55, Up 12% in pre market this morning.
Inhibitex Commences Dosing of Phase 2 Clinical Trial of INX-189 in HCV Infected Genotype 2/3 Patients
Inhibitex, Inc. (Nasdaq:INHX - News), announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients. The trial is designed to evaluate three once-daily doses of INX-189 (25 mg, 50 mg and 100 mg) administered in combination with pegylated interferon and ribavirin for 12 weeks, and also includes a control arm in which patients will receive placebo and standard of care treatment (a combination of pegylated interferon and ribavirin for 24 weeks). Each INX-189 combination treatment cohort in the trial will include 25 patients, and the control arm will include 15 patients.
Patients in the INX-189 containing treatment arms that achieve an extended rapid viral response, or eRVR, defined as having HCV RNA below the level of detection after 28 days and 12 weeks of dosing, will stop all therapy after 12 weeks. Those patients who do not achieve an eRVR will continue receiving pegylated interferon and ribavirin for 12 additional weeks.
Inhibitex Commences Dosing of Phase 2 Clinical Trial of INX-189 in HCV Infected Genotype 2/3 Patients
Inhibitex, Inc. (Nasdaq:INHX - News), announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients. The trial is designed to evaluate three once-daily doses of INX-189 (25 mg, 50 mg and 100 mg) administered in combination with pegylated interferon and ribavirin for 12 weeks, and also includes a control arm in which patients will receive placebo and standard of care treatment (a combination of pegylated interferon and ribavirin for 24 weeks). Each INX-189 combination treatment cohort in the trial will include 25 patients, and the control arm will include 15 patients.
Patients in the INX-189 containing treatment arms that achieve an extended rapid viral response, or eRVR, defined as having HCV RNA below the level of detection after 28 days and 12 weeks of dosing, will stop all therapy after 12 weeks. Those patients who do not achieve an eRVR will continue receiving pegylated interferon and ribavirin for 12 additional weeks.
Monday, October 25, 2010
Citigroup Inc. (NYSE:C) Upgraded By Goldman Sachs
By Tim - http://stockstobuy.org
Shares of Citigroup Inc (NYSE:C) have been added to the conviction buy list at Goldman Sachs. Citigroup Inc stock is trading up $0.10 to $4.21 in early trading. Citigroup will have resistance located at $4.30 but then nothing major until $4.55-$4.70. Citigroup remains a solid long term buy below $4.00.
Citigroup has a current price target at Goldman located at $5.50.
For more updates on the stock market, visit http://daytradingstockblog.blogspot.com
Shares of Citigroup Inc (NYSE:C) have been added to the conviction buy list at Goldman Sachs. Citigroup Inc stock is trading up $0.10 to $4.21 in early trading. Citigroup will have resistance located at $4.30 but then nothing major until $4.55-$4.70. Citigroup remains a solid long term buy below $4.00.
Citigroup has a current price target at Goldman located at $5.50.
For more updates on the stock market, visit http://daytradingstockblog.blogspot.com
Friday, August 14, 2009
Citigroup ( C ) Stock Upgraded to Buy - 8/14/09
August 14, 2009 - Shares of Citigroup Inc (C:NYSE) are spiking above $4.20 in pre market this morning after Bank of America/Merrill is upgrading shares from Underperform to Buy.
Citigroup shares have been on fire lately due to improving stock market conditions as well as huge index buying. There is major resistance located in the $4.40's with the 200 day moving average located at $4.49. A close over the 200 day moving average would be big and a run toward $5 would occur.
If Citigroup closes over $5, I believe you would see additional heavy buying as Mutual Funds get back in due to the stock being over $5 again. Some funds even wait until $5.50-$6.
Keep an eye on this situation!
Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Hot OTC Stocks
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Citigroup shares have been on fire lately due to improving stock market conditions as well as huge index buying. There is major resistance located in the $4.40's with the 200 day moving average located at $4.49. A close over the 200 day moving average would be big and a run toward $5 would occur.
If Citigroup closes over $5, I believe you would see additional heavy buying as Mutual Funds get back in due to the stock being over $5 again. Some funds even wait until $5.50-$6.
Keep an eye on this situation!
Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Hot OTC Stocks
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Subscribe to:
Posts (Atom)